Chongqing Taiji Industry Group Co Ltd banner
C

Chongqing Taiji Industry Group Co Ltd
SSE:600129

Watchlist Manager
Chongqing Taiji Industry Group Co Ltd
SSE:600129
Watchlist
Price: 15.96 CNY -0.56% Market Closed
Market Cap: ¥8.8B

EV/OCF

22.3
Current
8%
Cheaper
vs 3-y average of 24.3

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
22.3
=
Enterprise Value
¥13.2B
/
Operating Cash Flow
¥583.9m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
22.3
=
Enterprise Value
¥13.2B
/
Operating Cash Flow
¥583.9m

Valuation Scenarios

Chongqing Taiji Industry Group Co Ltd is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (24.3), the stock would be worth ¥17.37 (9% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-7%
Maximum Upside
+9%
Average Upside
1%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 22.3 ¥15.96
0%
3-Year Average 24.3 ¥17.37
+9%
5-Year Average 21.8 ¥15.57
-2%
Industry Average 23.8 ¥16.98
+6%
Country Average 20.8 ¥14.87
-7%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
CN
Chongqing Taiji Industry Group Co Ltd
SSE:600129
8.8B CNY 22.3 73
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 51.6 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 23.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 15.2 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.1 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.2 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 18.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.5 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 17.2 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 10.6 16.8

Market Distribution

In line with most companies in China
Percentile
52nd
Based on 6 190 companies
52nd percentile
22.3
Low
0 — 11.5
Typical Range
11.5 — 39.2
High
39.2 —
Distribution Statistics
China
Min 0
30th Percentile 11.5
Median 20.8
70th Percentile 39.2
Max 266 666.7

Chongqing Taiji Industry Group Co Ltd
Glance View

Market Cap
8.8B CNY
Industry
Pharmaceuticals

Amidst the sprawling urban landscape of Chongqing, a city often enveloped in a mystical cloak of fog, stands Chongqing Taiji Industry Group Co Ltd., a distinguished entity in the realm of pharmaceuticals. Commanding a legacy that spans over a century, Taiji Industry has mastered the delicate fusion of traditional Chinese medicine with modern pharmaceutical processes. This synthesis has propelled the company to the forefront of China's healthcare sector. The company’s operations revolve around robust research and development, manufacturing, and distribution, focusing on a diverse array of pharmaceutical products, health supplements, and TCM (Traditional Chinese Medicine) remedies. Seamlessly integrating innovation with traditional wisdom, the group has built an extensive portfolio catering to a wide range of medical needs, from cardiovascular treatments to neurological supports. Financially, Taiji Industry's prowess is underpinned by its diverse revenue streams, primarily flowing from its broad spectrum of medicinal drugs and health products. The company has capitalized on its established brand and extensive distribution networks, which span across the vast Chinese landscape and extend their reach into international markets. Their stronghold in distribution is further solidified by strategic collaborations with healthcare providers and retail pharmacy chains, ensuring reliable market penetration and accessibility to the end consumer. This well-oiled machine not only secures Taiji's position as a major pharmaceutical player but also drives its financial growth, allowing the company to invest continuously in innovation, quality enhancement, and market expansion. The synergistic blend of tradition and modernity continues to propel Taiji Industry through the ever-evolving pharmaceutical landscape.

Intrinsic Value
22.89 CNY
Undervaluation 30%
Intrinsic Value
Price ¥15.96
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett